Abstract
The increasing costs of treating rheumatic diseases has presented a serious challenge to contain the projected expenditures of $96.8 billion by the year 2000. This includes both direct and indirect costs to the patient and society. These expenditures include physician care, prescribed drugs, patient aids, physical and occupational therapy, nursing care, hospitalization, and nursing home care. Indirect costs include lost wages, insurance indemnification, loss of productivity, disability and pension payments, and rehabilitation expenses rendered by government agencies. Sparcity of data presents problems in addressing this onerous tax on society. In 1985 Baum reported that 66.5 million prescriptions for nonsalicylate nonsteroidal anti-inflammatory drugs (NSAIDs) were prescribed in the United States at a cost of over $1 billion. Salicylates were not included. Cost-effectiveness of salicylates v nonsalicylate NSAIDs is reviewed. Most studies carried out have not appropriately presented these comparative data. ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
